Finance

Daftar
Mengapa 4142 turun 6,62%?
Pelajari Lebih Lanjut
4142:TPE
Adimmune Corp
NT$14,80
-6,62%
(-1,05) 1 HR
20 Nov, 13.30.09 GMT+8  ·   TWD
Semua simbol
SimbolHargaPerubahanPersentase Perubahan
Membuat insight teratas untuk 4142...
Pembukaan
NT$15,75
Tinggi
NT$15,75
Rendah
NT$14,80
Kapitalisasi pasar
6,36 M
Volume rata-rata
1,13 jt
Volume
1,63 jt
Rasio P/E
85,76
Harga tinggi dalam 52 minggu terakhir
NT$21,50
Harga rendah dalam 52 minggu terakhir
NT$14,80
EPS
NT$0,17
Saham beredar
235,29 jt
Jumlah karyawan
564
Pembukaan
NT$15,75
Tinggi
NT$15,75
Rendah
NT$14,80
Kapitalisasi pasar
6,36 M
Volume rata-rata
1,13 jt
Volume
1,63 jt
Rasio P/E
85,76
Harga tinggi dalam 52 minggu terakhir
NT$21,50
Harga rendah dalam 52 minggu terakhir
NT$14,80
EPS
NT$0,17
Saham beredar
235,29 jt
Jumlah karyawan
564
Artikel berita
Dari sumber web dan partner berita
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Tentang Adimmune Corp
CEO-
Karyawan564
Didirikan1965
Kantor Pusat-
SektorHealth Care
Industri-
Laporan sebelumnyaSemua nilai dalam TWD
Loading Previous Earnings...
Pendapatan
Penghasilan bersih
Semua nilai dalam TWD
Des 2025
Mar 2026
Jun 2026
Sep 2026
Pendapatan
745,46 jt
82,32 jt
66,76 jt
715,67 jt
Harga pokok penjualan
376,00 jt
156,87 jt
129,59 jt
413,47 jt
Biaya pendapatan
376,00 jt
156,87 jt
129,59 jt
413,47 jt
Biaya riset dan pengembangan
74,68 jt
45,44 jt
30,55 jt
27,96 jt
Total biaya riset dan pengembangan
-
-
-
-
Biaya penjualan, umum, dan administrasi
94,80 jt
79,22 jt
79,34 jt
84,37 jt
Biaya operasional
197,18 jt
124,66 jt
109,88 jt
112,33 jt
Total biaya operasional
573,18 jt
281,54 jt
239,47 jt
525,80 jt
Penghasilan operasional
172,28 jt
-199,22 jt
-172,71 jt
189,87 jt
Penghasilan non-operasional lainnya
10,40 jt
710,00 rb
2,18 jt
2,03 jt
EBT termasuk item luar biasa
200,77 jt
-200,47 jt
-172,95 jt
185,53 jt
EBT tidak termasuk item luar biasa
200,30 jt
-198,95 jt
-172,95 jt
185,53 jt
Beban pajak penghasilan
-
-
-
-
Tarif pajak efektif
-
-
-
-
Biaya operasional lainnya
-
-
-
-
Penghasilan bersih
220,42 jt
-185,54 jt
-160,23 jt
198,10 jt
Margin laba bersih
29,57%
-225,41%
-240,02%
27,68%
Penghasilan per saham
-
-
-
0,47
Penghasilan bunga dan investasi
9,92 jt
3,10 jt
6,47 jt
3,04 jt
Beban bunga
-10,40 jt
-7,40 jt
-6,95 jt
-9,42 jt
Beban bunga bersih
-475,00 rb
-4,30 jt
-480,00 rb
-6,38 jt
Biaya depresiasi dan amortisasi
-
-
-
-
EBITDA
219,90 jt
-156,74 jt
-128,36 jt
266,40 jt
Keuntungan atau kerugian dari penjualan aset
-3,00 rb
-
-
-
Acara mendatang
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut
Aplikasi Google